Holen Sie sich die Stockscreener-App
17.37
0.00%
0.00
Handel nachbörslich:
17.37
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
DYN stock gains as it gears up for accelerated approval of DMD therapy: Wall Street sees 140% upside - MSN
(DYN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Dyne spikes as late-stage trial for Duchenne therapy gets underway - MSN
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares - AOL.com
Insider Buying: Brian Posner Acquires Additional Shares of Dyne Therapeutics Inc (DYN) - GuruFocus
Dyne Therapeutics (DYN) director buys 2,500 Common Stock shares - Stock Titan
Dyne Therapeutics: 'Strong Buy' Due To Upcoming Z-Rostudirsen BLA Submission (DYN) - Seeking Alpha
Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients - TradingView
DYN Stock Gains As It Gears Up For Accelerated Approval Of DMD Therapy: Wall Street Sees 140% Upside - Stocktwits
United States Duchenne Muscular Dystrophy Therapeutics Market - openPR.com
A Look At Dyne Therapeutics (DYN) Valuation As Phase 3 FORZETTO Trial Marks Key Development Milestone - Yahoo Finance
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Dyne Therapeutics, Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Dyne Therapeutics (DYN) Launches Phase 3 FORZETTO Trial for Duch - GuruFocus
Dyne Therapeutics Launches Late-Stage Trial for DMD Therapy - Intellectia AI
Dyne stock spikes as Duchenne trial launches (DYN:NASDAQ) - Seeking Alpha
DYN: 2026 will focus on DMD and DM1 launches, confirmatory trials, and pipeline expansion - TradingView
DYN: 2026 targets commercial launches for DMD and DM1, with pipeline expansion and strong clinical data - TradingView
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy Ahead of Planned BLA Submission for U.S. Accelerated Approval - Investing News Network
Dyne Therapeutics Initiates Phase 3 Trial of Potential Duchenne Muscular Dystrophy Treatment - Moomoo
Duchenne trial of z-rostudirsen tied to U.S. accelerated approval bid - Stock Titan
Dyne Therapeutics launches phase 3 trial for DMD treatment - Investing.com
Dyne Therapeutics launches phase 3 trial for DMD treatment By Investing.com - Investing.com Australia
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval - The Manila Times
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares - The Motley Fool
MSN Money - MSN
LifeSci Capital Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $44 - Moomoo
DYN Maintained by Evercore ISI Group -- Price Target Lowered to $33 - GuruFocus
Janus Henderson reports 13.65M shares in Dyne Therapeutics (NASDAQ: DYN) - Stock Titan
T. Rowe Price (NASDAQ: DYN) holds 30.8M shares, a 18.7% stake - Stock Titan
DYN Stock Chart | DYNE THERAPEUTICS INC (NASDAQ:DYN) - ChartMill
Insider Selling: Dyne Therapeutics (NASDAQ:DYN) CFO Sells 1,448 Shares of Stock - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Insider Sells $28,715.04 in Stock - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) CEO John Cox Sells 3,311 Shares - MarketBeat
Dyne therapeutics CFO Lucera sells $26,585 in company stock By Investing.com - Investing.com Canada
Breakthrough Findings from Dyne Therapeutics (DYN) Enhance Marke - GuruFocus
Dyne therapeutics CFO Lucera sells $26,585 in company stock - Investing.com
[Form 4] Dyne Therapeutics, Inc. Insider Trading Activity - Stock Titan
Dyne Therapeutics (DYN) CCO auto-sells shares to cover RSU taxes - Stock Titan
Dyne Therapeutics (DYN) CFO logs automatic 1,448-share tax-related sale - Stock Titan
Dyne Therapeutics (DYN) CEO’s 3,311-share sale is automatic tax withholding - Stock Titan
Lifesci Capital Issues Optimistic Outlook for DYN Earnings - MarketBeat
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):